Are newly produced T and B lymphocytes and T-cell receptor repertoire diversity reduced in peripheral blood of fingolimod-treated multiple sclerosis patients?
These results do not have direct clinical implications but they may be useful for further understanding the mode of action of this immunotherapy for multiple sclerosis patients.
KZ-41 protects REC against melphalan-induced upregulation of ICAM-1 and apoptosis through p38 MAPK-dependent pathways.